✦ LIBER ✦

Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer

✍ Scribed by Barnett, Jason C.; Alvarez Secord, Angeles; Cohn, David E.; Leath, Charles A.; Myers, Evan R.; Havrilesky, Laura J.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Incorporation of Bevacizumab in the Prim

✍ Burger, Robert A.; Brady, Mark F.; Bookman, Michael A.; Fleming, Gini F.; Monk, 📂 Article 📅 2011 🏛 Massachusetts Medical Society 🌐 English ⚖ 690 KB

Cost-effectiveness of a predictive bioma

✍ J. Barnett; A. Alvarez-Secord; D. Cohn; C. Leath; B. Peterson; E. Myers; L. Havr 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 133 KB

A cost effective strategy of bevacizumab

✍ J. Chan; T. Herzog; L. Hu; T. Kiet; B. Monk; D. Kapp; X. Yu 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 75 KB

Cost-Effectiveness Of Prophylaxis Treatm

✍ Fust, K.; Li, X.; Maschio, M.; Barron, R.; Weinstein, M.C.; Parthan, A.; Walli-A 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

Is paclitaxel a more cost-effective choi

✍ Kushnir, C.L.; Frick, K.; Zhao, Z.; Giuntoli, R.L. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 101 KB

Cost-effectiveness of prophylaxis treatm

✍ Fust, Kelly; Li, Xiaoyan; Maschio, Michael; Barron, Richard; Weinstein, Milton C 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 457 KB